v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses    
Research and development $ 8,290 $ 11,125
General and administrative 12,639 5,994
Total operating expenses 20,929 17,119
Other operating income 329 205
Loss from operations (20,600) (16,914)
Other income/(expense):    
Interest income 556 775
Interest expense (13) (12)
Research and development incentives 302 594
Other income 75 0
Total other income, net 920 1,357
Loss before income tax (19,680) (15,557)
Tax benefit 22 37
Net loss (19,658) (15,520)
Net loss attributable to noncontrolling interest 10 31
Net loss attributable to Barinthus Biotherapeutics plc shareholders $ (19,648) $ (15,489)
Weighted-average ordinary shares outstanding, basic (in shares) 40,265,216 38,773,482
Weighted-average ordinary shares outstanding, diluted (in shares) 40,265,216 38,773,482
Net loss per share attributable to ordinary shareholders, basic (in usd per share) $ (0.49) $ (0.40)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share) $ (0.49) $ (0.40)
Net loss $ (19,658) $ (15,520)
Other comprehensive gain/(loss) – foreign currency translation adjustments 4,646 (1,577)
Comprehensive loss (15,012) (17,097)
Comprehensive loss attributable to noncontrolling interest 7 28
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders $ (15,005) $ (17,069)